- Home
- GMEX vs VBIO Comparison
GMEX vs VBIO Comparison
Compare GMEX & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMEX | VBIO |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3M | 1.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GMEX | VBIO |
|---|---|---|
| Price | $0.46 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 253.0K | ★ 312.7K |
| Earning Date | 11-02-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.12 |
| 52 Week High | $4.57 | $812.50 |
Technical Indicators
Market Signals| Indicator | GMEX | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 21.34 |
| Support Level | $0.31 | $0.12 |
| Resistance Level | $1.23 | $4.39 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.07 | 1.00 |
| Stochastic Oscillator | 0.56 | 3.62 |
Price Performance
Historical ComparisonAbout GMEX GMEX ROBOTICS CORPORATION Class A Ordinary Shares
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.